alterations,drugs,approvedIndications,level,fdaLevel,levelAssociatedCancerType,levelExcludedCancerTypes,pmids,abstracts,description
['Oncogenic Mutations'],"[{'ncitCode': 'C198690', 'drugName': 'PRT3789'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 319, 'code': 'ESCA', 'color': 'LightSkyBlue', 'name': 'Esophageal Adenocarcinoma', 'mainType': {'id': None, 'name': 'Esophagogastric Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Esophagus/Stomach', 'children': {}, 'parent': 'EGC', 'level': 3, 'tumorForm': 'SOLID'}",[],[],"[{'link': 'https://www.annalsofoncology.org/article/S0923-7534(24)02189-6/fulltext', 'abstract': 'Guo, R. et al., Abstract# 603O, ESMO 2024.'}, {'link': 'https://aacrjournals.org/cancerres/article/82/12_Supplement/3263/703325/Abstract-3263-Preclinical-characterization-of', 'abstract': 'Hulse, M. et al., Abstract# 3263, AACR 2022.'}]","PRT3789 is an orally available, small molecule SMARCA2 degrader. There are promising clinical data of response to PRT3789 in patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal adenocarcinoma. In the Phase I (NCT05639751) trial of PRT3789 in 26 patients with SMARCA4-mutated NSCLC (n=24) or esophageal adenocarcinoma (n=2), three patients (n=2, esophageal adenocarcinoma; n=1, NSCLC) achieved a partial response and 26% (7/26) of patients demonstrated tumor shrinkage (Abstract: Guo, R. et al., Abstract# 603O, ESMO 2024. https://www.annalsofoncology.org/article/S0923-7534(24)02189-6/fulltext). In vivo studies with cell-derived and patient-derived NSCLC xenograft models expressing SMARCA4 deletion mutations demonstrate sensitivity to PRT3789 as measured by tumor growth inhibition (Abstract: Hulse, M. et al., Abstract# 3263, AACR 2022. https://aacrjournals.org/cancerres/article/82/12_Supplement/3263/703325/Abstract-3263-Preclinical-characterization-of)."
['Oncogenic Mutations'],"[{'ncitCode': 'C198690', 'drugName': 'PRT3789'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],[],"[{'link': 'https://www.annalsofoncology.org/article/S0923-7534(24)02189-6/fulltext', 'abstract': 'Guo, R. et al., Abstract# 603O, ESMO 2024.'}, {'link': 'https://aacrjournals.org/cancerres/article/82/12_Supplement/3263/703325/Abstract-3263-Preclinical-characterization-of', 'abstract': 'Hulse, M. et al., Abstract# 3263, AACR 2022.'}]","PRT3789 is an orally available, small molecule SMARCA2 degrader. There are promising clinical data of response to PRT3789 in patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal adenocarcinoma. In the Phase I (NCT05639751) trial of PRT3789 in 26 patients with SMARCA4-mutated NSCLC (n=24) or esophageal adenocarcinoma (n=2), three patients (n=2, esophageal adenocarcinoma; n=1, NSCLC) achieved a partial response and 26% (7/26) of patients demonstrated tumor shrinkage (Abstract: Guo, R. et al., Abstract# 603O, ESMO 2024. https://www.annalsofoncology.org/article/S0923-7534(24)02189-6/fulltext). In vivo studies with cell-derived and patient-derived NSCLC xenograft models expressing SMARCA4 deletion mutations demonstrated sensitivity to PRT3789 as measured by tumor growth inhibition (Abstract: Hulse, M. et al., Abstract# 3263, AACR 2022. https://aacrjournals.org/cancerres/article/82/12_Supplement/3263/703325/Abstract-3263-Preclinical-characterization-of)."
